GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S...

CAMBRIDGE, Mass., Sept. 18, 2024. Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small...

HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical trials for ASC30, the first and only small molecule GLP-1 receptor (GLP-1R) agonist that...

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2024. Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a Phase 1 trial of TTX-030, a potential first-in-class, anti-CD39 antibody, in...

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced new positive interim data in Huntington's disease (HD) from the ongoing...

9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care...